Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2012-08-01 | Anthony A. DiTonno has served as a director since December 2011. Mr. DiTonno serves on the Compensation Committee. 2012 Director Compensation: Anthony A. DiTonno - Total: $26,585. |
| 2015-08-17 | Anthony A. DiTonno has served as a director since December 2011. Mr. DiTonno serves as a member of the Compensation Committee. 2015 Director Compensation table shows total compensation of $89,607. |
| 2016-04-26 | Anthony A. DiTonno has served as a director since December 2011. Mr. DiTonno serves as chair of the Compensation Committee. Transition Period 2015 Director Compensation: $55,033 total. |
| 2017-04-28 | Anthony A. DiTonno has served as a director since December 2011. Mr. DiTonno serves as chair of the Compensation Committee. |
| 2018-04-20 | Anthony A. DiTonno has served as a director since December 2011. Mr. DiTonno serves as chair of the Compensation Committee. |
| 2019-04-19 | Anthony A. DiTonno has served as a director since December 2011 and as our Chief Executive Officer since June 2018. From January 2013 until May 2018, Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices. From April 2003 until December 2011, Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area (“Neurogesx”). During his time at Neurogesx, Mr. DiTonno also served on its board of directors. Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financings, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union. Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories. Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. (Rhône Poulenc Rorer) and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph’s University. We believe that Mr. DiTonno’s extensive corporate experience and financial background qualify him to serve on our Board and provides valuable insight to the Company. Mr. DiTonno’s total 2018 compensation was $645,766. |
| 2020-04-29 | Anthony A. DiTonno has served as a director since December 2011 and as our Chief Executive Officer since June 2018. During Mr. DiTonno’s service as our Chief Executive Officer, he has not received compensation for his service on our Board. |
| 2021-04-30 | Anthony A. DiTonno has served as a director since December 2011 and as our Chief Executive Officer since June 2018. From January 2013 until May 2018, Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices. |
Data sourced from SEC filings. Last updated: 2025-06-16